{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:10:33Z","timestamp":1790644233117,"version":"4.1.0"},"reference-count":71,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI093716"],"award-info":[{"award-number":["R01 AI093716"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["OPP1132451"],"award-info":[{"award-number":["OPP1132451"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32 GM008666"],"award-info":[{"award-number":["T32 GM008666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012640","name":"ExxonMobil Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012640","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI169892"],"award-info":[{"award-number":["R01 AI169892"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,21]]},"abstract":"<jats:p>\n                    Drug resistance remains a major obstacle to malaria control and eradication efforts, necessitating the development of novel therapeutic strategies to treat this disease. Drug combinations based on collateral sensitivity, wherein resistance to one drug causes increased sensitivity to the partner drug, have been proposed as an evolutionary strategy to suppress the emergence of resistance in pathogen populations. In this study, we explore collateral sensitivity between compounds targeting the\n                    <jats:italic>Plasmodium<\/jats:italic>\n                    dihydroorotate dehydrogenase (DHODH). We profiled the cross-resistance and collateral sensitivity phenotypes of several DHODH mutant lines to a diverse panel of DHODH inhibitors. We focus on one compound, TCMDC-125334, which was active against all mutant lines tested, including the DHODH C276Y line, which arose in selections with the clinical candidate DSM265. In six selections with TCMDC-125334, the most common mechanism of resistance to this compound was copy number variation of the\n                    <jats:italic>dhodh<\/jats:italic>\n                    locus, although we did identify one mutation, DHODH I263S, which conferred resistance to TCMDC-125334 but not DSM265. We found that selection of the DHODH C276Y mutant with TCMDC-125334 yielded additional genetic changes in the\n                    <jats:italic>dhodh<\/jats:italic>\n                    locus. These double mutant parasites exhibited decreased sensitivity to TCMDC-125334 and were highly resistant to DSM265. Finally, we tested whether collateral sensitivity could be exploited to suppress the emergence of resistance in the context of combination treatment by exposing wildtype parasites to both DSM265 and TCMDC-125334 simultaneously. This selected for parasites with a DHODH V532A mutation which were cross-resistant to both compounds and were as fit as the wildtype parent in vitro. The emergence of these cross-resistant, evolutionarily fit parasites highlights the mutational flexibility of the DHODH enzyme.\n                  <\/jats:p>","DOI":"10.7554\/elife.85023","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:15:13Z","timestamp":1695363313000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.85023","source":"Crossref","is-referenced-by-count":8,"title":["Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance"],"prefix":"10.7554","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-7876","authenticated-orcid":true,"given":"Rebecca EK","family":"Mandt","sequence":"first","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health","place":["Boston, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline R","family":"Luth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Host Pathogen Systems and Therapeutics, Department of Pediatrics, University of California, San Diego","place":["San Diego, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Tye","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Systems Biology, Massachusetts General Hospital","place":["Boston, United States"]},{"name":"Harvard Graduate School of Arts and Sciences","place":["Cambridge, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Mazitschek","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health","place":["Boston, United States"]},{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Systems Biology, Massachusetts General Hospital","place":["Boston, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ottilie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Host Pathogen Systems and Therapeutics, Department of Pediatrics, University of California, San Diego","place":["San Diego, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-2113","authenticated-orcid":true,"given":"Elizabeth A","family":"Winzeler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Host Pathogen Systems and Therapeutics, Department of Pediatrics, University of California, San Diego","place":["San Diego, United States"]},{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"Skaggs School of Pharmaceutical Sciences, University of California, San Diego","place":["La Jolla, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Lafuente-Monasterio","sequence":"additional","affiliation":[{"name":"Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Gamo","sequence":"additional","affiliation":[{"name":"Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyann F","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health","place":["Boston, United States"]},{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Disease and Microbiome Program, The Broad Institute","place":["Cambridge, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-7643","authenticated-orcid":true,"given":"Amanda K","family":"Lukens","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health","place":["Boston, United States"]},{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Disease and Microbiome Program, The Broad Institute","place":["Cambridge, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/molbev\/msz109","article-title":"Limited evolutionary conservation of the phenotypic effects of antibiotic resistance mutations","volume":"36","author":"Apjok","year":"2019","journal-title":"Molecular Biology and Evolution"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"21847","DOI":"10.1074\/jbc.M501100200","article-title":"High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"280","author":"Baldwin","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"bib3","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.51481","article-title":"Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen Pseudomonas aeruginosa","volume":"8","author":"Barbosa","year":"2019","journal-title":"eLife"},{"key":"bib4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3292","article-title":"Multidrug evolutionary strategies to reverse antibiotic resistance","volume":"351","author":"Baym","year":"2016","journal-title":"Science"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.14745\/ccdr.v45i23a02","article-title":"Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present","volume":"45","author":"Bodie","year":"2019","journal-title":"Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","article-title":"Benefits of using multiple first-line therapies against malaria","volume":"105","author":"Boni","year":"2008","journal-title":"PNAS"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"33054","DOI":"10.1074\/jbc.M110.162081","article-title":"Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model","volume":"285","author":"Booker","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"bib8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003293","article-title":"Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families","volume":"9","author":"Bopp","year":"2013","journal-title":"PLOS Genetics"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Current Opinion in Virology"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14787210.2020.1705155","article-title":"Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction","volume":"18","author":"Coates","year":"2020","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/mol.61.1.35","article-title":"Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum","volume":"61","author":"Cooper","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1126\/science.aan4472","article-title":"Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics","volume":"359","author":"Cowell","year":"2018","journal-title":"Science"},{"key":"bib13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008278","article-title":"Antibiotic interactions shape short-term evolution of resistance in E. faecalis","volume":"16","author":"Dean","year":"2020","journal-title":"PLOS Pathogens"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.jmb.2015.05.011","article-title":"Negative Epistasis and evolvability in TEM-1 \u03b2-Lactamase--The Thin line between an Enzyme\u2019s Conformational Freedom and Disorder","volume":"427","author":"Dellus-Gur","year":"2015","journal-title":"Journal of Molecular Biology"},{"key":"bib15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00791-8","article-title":"Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer","volume":"7","author":"Dhawan","year":"2017","journal-title":"Scientific Reports"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"The Lancet. Respiratory Medicine"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.chembiol.2011.09.016","article-title":"Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors","volume":"18","author":"Dong","year":"2011","journal-title":"Chemistry & Biology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.pt.2021.04.006","article-title":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","volume":"37","author":"Duffey","year":"2021","journal-title":"Trends in Parasitology"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/0006-2952(93)90264-w","article-title":"Plasmodium falciparum: effects of amantadine, an antiviral, on chloroquine-resistant and -sensitive parasites in vitro and its influence on chloroquine activity","volume":"45","author":"Evans","year":"1993","journal-title":"Biochemical Pharmacology"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1021\/cb500616x","article-title":"Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials","volume":"10","author":"Flannery","year":"2015","journal-title":"ACS Chemical Biology"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2012.02.021","article-title":"Outwitting evolution: fighting drug-resistant TB, malaria, and HIV","volume":"148","author":"Goldberg","year":"2012","journal-title":"Cell"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nchembio.1911","article-title":"Synergistic, collaterally sensitive \u03b2-lactam combinations suppress resistance in MRSA","volume":"11","author":"Gonzales","year":"2015","journal-title":"Nature Chemical Biology"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson","year":"2017","journal-title":"The Lancet Infectious Diseases"},{"key":"bib24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003375","article-title":"Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications","volume":"9","author":"Guler","year":"2013","journal-title":"PLOS Pathogens"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrmicro.2017.161","article-title":"Drug resistance in Plasmodium","volume":"16","author":"Haldar","year":"2018","journal-title":"Nature Reviews. Microbiology"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","article-title":"Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study","volume":"19","author":"Hamilton","year":"2019","journal-title":"The Lancet. Infectious Diseases"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pt.2010.09.005","article-title":"How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance","volume":"27","author":"Hastings","year":"2011","journal-title":"Trends in Parasitology"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"13977","DOI":"10.1073\/pnas.0805965105","article-title":"Accelerated evolution of resistance in multidrug environments","volume":"105","author":"Hegreness","year":"2008","journal-title":"PNAS"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/eva.12530","article-title":"Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites","volume":"11","author":"Huijben","year":"2018","journal-title":"Evolutionary Applications"},{"key":"bib30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006609","article-title":"Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development","volume":"5","author":"Imamovic","year":"2013","journal-title":"Science Translational Medicine"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(18)30471-7","article-title":"Antimicrobial resistance: a threat to global health","volume":"18","author":"Jee","year":"2018","journal-title":"The Lancet. Infectious Diseases"},{"key":"bib32","doi-asserted-by":"publisher","DOI":"10.1101\/082107","article-title":"Population Diversity Jeopardizes the Efficacy of Antibiotic Cycling","volume-title":"bioRxiv","author":"Jiao","year":"2016"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.molcel.2004.09.012","article-title":"Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents","volume":"15","author":"Johnson","year":"2004","journal-title":"Molecular Cell"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1128\/AAC.01607-06","article-title":"Assessment and continued validation of the Malaria SYBR Green I-Based Fluorescence Assay for use in Malaria Drug Screening","volume":"51","author":"Johnson","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"bib35","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination Therapy for Tuberculosis: lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"14494","DOI":"10.1073\/pnas.1409800111","article-title":"Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance","volume":"111","author":"Kim","year":"2014","journal-title":"PNAS"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"E6863","DOI":"10.1073\/pnas.1806109115","article-title":"Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance","volume":"115","author":"Kirkman","year":"2018","journal-title":"PNAS"},{"key":"bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2307\/3280287","article-title":"Synchronization of Plasmodium falciparum erythrocytic stages in culture","volume":"65","author":"Lambros","year":"1979","journal-title":"The Journal of Parasitology"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/PL00012925","article-title":"New cases of negative cross-resistance between Fungicides, including Sterol Biosynthesis inhibitors","volume":"66","author":"Leroux","year":"2000","journal-title":"Journal of General Plant Pathology"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"The Lancet. Infectious Diseases"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.2174\/0929867324666161118130238","article-title":"MRP1-dependent Collateral sensitivity of multidrug-resistant Cancer Cells: identifying selective modulators inducing cellular Glutathione depletion","volume":"24","author":"Lorendeau","year":"2017","journal-title":"Current Medicinal Chemistry"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"12025","DOI":"10.1073\/pnas.0905922106","article-title":"Stepwise acquisition of pyrimethamine resistance in the malaria parasite","volume":"106","author":"Lozovsky","year":"2009","journal-title":"PNAS"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1073\/pnas.1320886110","article-title":"Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance","volume":"111","author":"Lukens","year":"2014","journal-title":"PNAS"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/infdis\/jiu565","article-title":"Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors","volume":"211","author":"Lukens","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"key":"bib45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000515","article-title":"Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance","volume":"17","author":"Maltas","year":"2019","journal-title":"PLOS Biology"},{"key":"bib46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-63","article-title":"Identification of pathogen genomic variants through an integrated pipeline","volume":"15","author":"Manary","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"bib47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1636","article-title":"In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model","volume":"11","author":"Mandt","year":"2019","journal-title":"Science Translational Medicine"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/ng.3767","article-title":"Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance","volume":"49","author":"Manson","year":"2017","journal-title":"Nature Genetics"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"The Lancet. Infectious Diseases"},{"key":"bib50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009940","article-title":"Prediction of resistance development against drug combinations by collateral responses to component drugs","volume":"6","author":"Munck","year":"2014","journal-title":"Science Translational Medicine"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/infdis\/jix613","article-title":"A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation","volume":"217","author":"Murphy","year":"2018","journal-title":"The Journal of Infectious Diseases"},{"key":"bib52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08098-6","article-title":"Antibiotic collateral sensitivity is contingent on the repeatability of evolution","volume":"10","author":"Nichol","year":"2019","journal-title":"Nature Communications"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature05572","article-title":"Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum","volume":"446","author":"Painter","year":"2007","journal-title":"Nature"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"35078","DOI":"10.1074\/jbc.M804990200","article-title":"Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"283","author":"Patel","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.jcim.5b00680","article-title":"Identification of New Human Malaria Parasite Plasmodium falciparum dihydroorotate dehydrogenase inhibitors by Pharmacophore and structure-based virtual screening","volume":"56","author":"Pavadai","year":"2016","journal-title":"Journal of Chemical Information and Modeling"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1021\/jm8001026","article-title":"Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum","volume":"51","author":"Phillips","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/187152610791163336","article-title":"Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy","volume":"10","author":"Phillips","year":"2010","journal-title":"Infectious Disorders Drug Targets"},{"key":"bib58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Science Translational Medicine"},{"key":"bib59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/genetics\/80.3.483","article-title":"Modification and inheritance of pleiotropic cross resistance and collateral sensitivity in Saccharomyces cerevisiae","volume":"80","author":"Rank","year":"1975","journal-title":"Genetics"},{"key":"bib60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005725","article-title":"Molecular Mechanisms for Drug Hypersensitivity induced by the Malaria Parasite\u2019s Chloroquine Resistance Transporter","volume":"12","author":"Richards","year":"2016","journal-title":"PLOS Pathogens"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/molbev\/msv006","article-title":"Collateral resistance and sensitivity modulate evolution of high-level resistance to Drug Combination Treatment in Staphylococcus aureus","volume":"32","author":"Rodriguez de Evgrafov","year":"2015","journal-title":"Molecular Biology and Evolution"},{"key":"bib62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08529-y","article-title":"Collateral sensitivity constrains resistance evolution of the CTX-M-15 \u03b2-lactamase","volume":"10","author":"Rosenkilde","year":"2019","journal-title":"Nature Communications"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"17980","DOI":"10.1074\/jbc.M114.558353","article-title":"In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth","volume":"289","author":"Ross","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1021\/acsinfecdis.7b00217","article-title":"Identification of collateral sensitivity to dihydroorotate dehydrogenase inhibitors in Plasmodium falciparum","volume":"4","author":"Ross","year":"2018","journal-title":"ACS Infectious Diseases"},{"key":"bib65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51711-x","article-title":"Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis","volume":"9","author":"Schmid","year":"2019","journal-title":"Scientific Reports"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","article-title":"In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa","volume":"199","author":"Sisowath","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"key":"bib67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010278","article-title":"Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance","volume":"18","author":"Small-Saunders","year":"2022","journal-title":"PLOS Pathogens"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","article-title":"Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening","volume":"48","author":"Smilkstein","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"bib69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007722","article-title":"Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents","volume":"15","author":"Stokes","year":"2019","journal-title":"PLOS Pathogens"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"The Lancet. Infectious Diseases"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1021\/acsinfecdis.8b00211","article-title":"Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the Clinical Candidate DSM265","volume":"5","author":"White","year":"2019","journal-title":"ACS Infectious Diseases"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/85023\/elife-85023-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/85023\/elife-85023-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/85023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T09:05:48Z","timestamp":1701680748000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/85023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":71,"alternative-id":["10.7554\/eLife.85023"],"URL":"https:\/\/doi.org\/10.7554\/elife.85023","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.07.486819","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2022.04.07.486819","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2022.04.07.486819","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"accession","id":"MZ571149","asserted-by":"subject"},{"id-type":"accession","id":"MZ571150","asserted-by":"subject"},{"id-type":"accession","id":"MZ571151","asserted-by":"subject"},{"id-type":"accession","id":"MZ571152","asserted-by":"subject"},{"id-type":"accession","id":"MZ571153","asserted-by":"subject"},{"id-type":"accession","id":"MZ571154","asserted-by":"subject"},{"id-type":"accession","id":"MZ571155","asserted-by":"subject"},{"id-type":"accession","id":"MZ571156","asserted-by":"subject"},{"id-type":"accession","id":"MZ571157","asserted-by":"subject"},{"id-type":"accession","id":"MZ571158","asserted-by":"subject"},{"id-type":"accession","id":"PRJNA689594","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.85023.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.85023.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.85023.sa0","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e85023"}}